Cancer Risk & Early Detection
Empowering early diagnosis through advanced genomic screening technologies.
Early Intervention
Early detection can make all the difference. Our cancer genomics tests help identify inherited risks and detect cancer at its earliest stages—when treatment is most effective. By understanding each patient's unique genetic profile, we enable more precise diagnoses, timely interventions, and personalized care pathways.
Understand Your Risks
.png)
Gain valuable insights into inherited cancer risks through advanced genetic screening—empowering you and your doctors to make informed decisions about prevention and ongoing monitoring.
Detect Potential Signs
.png)
Identify early indicators of cancer through advanced genomic insights—supporting prompt investigations, timely diagnosis, and more effective care planning.
Genomic Guidance for Treatment
Genomic testing uncovers key biomarkers that help doctors tailor more precise and personalized cancer treatment strategies, based on each patient's unique molecular profile.
Non-Invasive Testing
.png)
Receive accurate, reliable results through simple blood draws or tissue samples, minimizing the need for surgical procedures or hospital stays.
From Risk to Action
Our cancer genomics solutions bridge the gap between understanding inherited risks and making precise treatment decisions, using advanced molecular profiling and non-invasive early detection.
Comprehensive Cancer Genomics Testing
Hereditary Cancer Screening
Detect germline mutations across 316 cancer-related genes to identify inherited cancer risks, covering over 125 types of hereditary cancers for proactive health management.
Multi-Cancer Early Detection
Screen for over 80 types of cancer with a simple blood test. Detect early DNA signals to assess real-time cancer risk, supporting early detection and treatment planning.
Comprehensive Gene Profiling (CGP)
Analyze 523 genes from tumor tissue or biopsy samples to guide targeted therapies and immunotherapies—aligned with international treatment guidelines and comprehensive molecular signatures.
ctDNA Liquid Biopsy
A non-invasive blood-based genomic analysis of 523 genes, designed to guide treatment planning without the need for surgery, hospital stays, or complex procedures.
Cancer Recurrence Monitoring
Monitor minimal residual disease (MRD) using simple blood tests, tracking single or multiple gene changes to detect cancer recurrence early—when timely intervention is still possible.
.png)